Journal
ACS CENTRAL SCIENCE
Volume 8, Issue 2, Pages 192-204Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acscentsci.1c00910
Keywords
-
Categories
Funding
- Welch Foundation [A-1715]
- National Institute of Allergy and Infectious Diseases [R21AI164088]
- Texas A&M University President's Excellence Fund
- Texas AM X Grants
- TAMU COS Strategic Transformative Research Program
Ask authors/readers for more resources
The researchers developed an effective method to analyze the cellular potency of main protease (MPro) inhibitors for their toxicity and antiviral effect against SARS-CoV-2. Some antiviral agents showed weak cellular MPro inhibition potency, suggesting their involvement in interfering with other key steps in the virus life cycle. One of the inhibitors, MPI8, exhibited the highest cellular and antiviral potency, indicating the need for further research.
As an essential enzyme of SARS-CoV-2, main protease (MPro) triggers acute toxicity to its human cell host, an effect that can be alleviated by an MPro inhibitor. Using this toxicity alleviation, we developed an effective method that allows a bulk analysis of the cellular potency of MPro inhibitors. This novel assay is advantageous over an antiviral assay in providing precise cellular MPro inhibition information to assess an MPro inhibitor. We used this assay to analyze 30 known MPro inhibitors. Contrary to their strong antiviral effects and up to 10 mu M, 11a, calpain inhibitor II, calpain XII, ebselen, bepridil, chloroquine, and hydroxychloroquine showed relatively weak to undetectable cellular MPro inhibition potency implicating their roles in interfering with key steps other than just the MPro catalysis in the SARS-CoV-2 life cycle. Our results also revealed that MPI5, MPI6, MPI7, and MPI8 have high cellular and antiviral potency. As the one with the highest cellular and antiviral potency among all tested compounds, MPI8 has a remarkable cellular MPro inhibition IC50 value of 31 nM that matches closely to its strong antiviral effect with an EC50 value of 30 nM. Therefore, we cautiously suggest exploring MPI8 further for COVID-19 preclinical tests.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available